TMJ 'dysfunction' - Health implications

Within this forum, you will discover valuable insights on how a 'dysfunctional' jaw, dental arch anomalies, and various body asymmetries can contribute to illness from a unique perspective. This is your go-to resource for finding effective solutions and achieving lasting relief.
It is currently Fri, 29 Mar 2024, 11:00 am

All times are UTC [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
PostPosted: Thu, 25 Oct 2012, 7:02 pm 
Offline
Site Admin

Joined: Fri, 28 Sep 2012, 9:08 pm
Posts: 219
"Background: Spasticity is common in patients with multiple sclerosis (MS) and is a major contributor to disability. Sativex®, an oromucosal spray containing cannabis-based medicinal products, has been found to be effective in reducing spasticity symptoms. (We do not know where this evidence is. Perhaps someone can fill us up on this)

Objective: Our objective was to estimate the cost-effectiveness of Sativex® plus oral anti-spasticity medicines compared with the current standard treatment for moderate or severe spasticity in MS in the UK.
[color=#00000FF]Methods:[/color] A Markov model was used to assess the costs and benefits of Sativex® plus oral anti-spasticity medicines or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional QALY gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings.
Results: In the base case, Sativex® plus oral anti-spasticity medicines resulted in incremental costs of £7600 and a QALY gain of 0.15 per person over 5 years (ICER = £49 300 per QALY) [year 2009 data for costs]. Findings were sensitive to the costs of Sativex® (price and dose) and differences in utilities between responders and non-responders.
Conclusions: Using a willingness-to-pay threshold of £30 000 per QALY, Sativex® appears unlikely to be considered cost-effective by UK funders of healthcare for spasticity in MS."


Share on FacebookShare on TwitterShare on TuentiShare on SonicoShare on FriendFeedShare on OrkutShare on DiggShare on MySpaceShare on DeliciousShare on TechnoratiShare on TumblrShare on Google+
Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC [ DST ]


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Rules of the BoardThe teamDelete all board cookies
cron
Disclaimer: Please read our Disclaimer of warranties and limitation of liability
Also see information on Intellectual Property Rights
Before posting, please read our Board Rules
Powered by phpBB® Forum Software © phpBB Group